NCT02601378 is a Phase 1 clinical trial of LXS196 in Uveal Melanoma, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT02601378?

NCT02601378 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02601378?

Interventions in NCT02601378: LXS196, LXS196 and HDM201.

What condition does NCT02601378 study?

NCT02601378 studies Uveal Melanoma.

Is NCT02601378 still recruiting?

NCT02601378 is currently terminated. Last updated 29 September 2022.

Last reviewed 2022-09-29 · How we verify

NCT02601378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Terminated Phase 1 Last updated 29 September 2022

What this trial tests

Phase 1 trial testing LXS196 in Uveal Melanoma in 107 participants. Terminated before completion.

Timeline

1 February 2016

Primary endpoint
7 January 2022

7 January 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	107
Start date	1 February 2016
Primary completion	7 January 2022
Estimated completion	7 January 2022
Sites	6 locations across France, Netherlands, Norway, Australia, United States, Spain

Drugs / interventions tested

LXS196 — full drug profile →
LXS196 and HDM201 — full drug profile →

Conditions studied

Uveal Melanoma — all drugs for Uveal Melanoma →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Uveal Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting transcription factors in cancer - from undruggable to reality.
Bushweller JH. · · 2019 · cited 741× · PMID 31511663 · DOI 10.1038/s41568-019-0196-7
Targeting p53 pathways: mechanisms, structures, and advances in therapy.
Wang H, Guo M, Wei H, Chen Y. · · 2023 · cited 580× · PMID 36859359 · DOI 10.1038/s41392-023-01347-1
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Treatment of uveal melanoma: where are we now?
Yang J, Manson DK, Marr BP, Carvajal RD. · · 2018 · cited 229× · PMID 29497459 · DOI 10.1177/1758834018757175
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Khair DO, Bax HJ, Mele S, Crescioli S, et al · · 2019 · cited 181× · PMID 30941125 · DOI 10.3389/fimmu.2019.00453
The force awakens: metastatic dormant cancer cells.
Park SY, Park SY, Nam JS. · · 2020 · cited 149× · PMID 32300189 · DOI 10.1038/s12276-020-0423-z
Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.
Zhu H, Gao H, Ji Y, Zhou Q, et al · · 2022 · cited 141× · PMID 35831864 · DOI 10.1186/s13045-022-01314-3
Inhibition of p53 inhibitors: progress, challenges and perspectives.
Sanz G, Singh M, Peuget S, Selivanova G. · · 2019 · cited 106× · PMID 31310659 · DOI 10.1093/jmcb/mjz075

Verify or expand the search:

Other recruiting trials for Uveal Melanoma

Currently open trials in the same condition.

NCT07421739 — Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects · recruiting
NCT06070012 — Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06932757 — Adjuvant Quisinostat in High-Risk Uveal Melanoma · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
NCT06519266 — PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases · Phase 3 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02601378 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 29 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02601378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing